Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Kushim Tablets (Gushim) 45-count packages Recalled by B AND A TRADING CORPORATION Due to Marketed Without an Approved NDA/ANDA. FDA analysis found...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact B AND A TRADING CORPORATION directly.
Affected Products
Kushim Tablets (Gushim) 45-count packages, Label in foreign language
Quantity: 40 packages
Why Was This Recalled?
Marketed Without an Approved NDA/ANDA. FDA analysis found product to contain cinobufagin, bufalin, and bufotenine
Where Was This Sold?
This product was distributed to 2 states: NJ, NY
About B AND A TRADING CORPORATION
B AND A TRADING CORPORATION has 1 total recall tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report